TapewireFind a company

person · Reporting owner

Guy Wendy

Disclosed activity across 1 company

Tapewire entity
28265
SEC CIK
0001799360

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Processa Pharmaceuticals, Inc.PCSA · Entity 8210Chief Administrative OfficerJuly 26, 2026July 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Processa Pharmaceuticals, Inc.

Report date July 26, 2026 · Filed July 29, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct11,669 Reported balance After 2026-07-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-07-26 · Grant · Acquired 9,450 · Balance 11,669

F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

Common StockSEC Table I · non-derivativeDirect14,394 Reported balance Holding disclosure · report date 2026-07-26 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 14,394

Common StockSEC Table I · non-derivativeIndirectBy CorLyst, LLC333 Reported balance Holding disclosure · report date 2026-07-26 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 333

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96Direct6,000 Reported balance Holding disclosure · report date 2026-07-26 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance 6,000

F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 26, 2026 Filed Jul 29, 2026 00:22 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 9,450 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-26-001548 · form4.xml · derivative · entry 3

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,669

Underlying: Common Stock · 9,450 shares

Expires not disclosed

F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

Read SEC document
June 30, 2026 Filed Jul 1, 2026 20:20 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 2,436 $1.93 $4,701.48
Disclosure

SEC source: 0000897069-26-001484 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,394

Read SEC document
June 15, 2026 Filed Jun 16, 2026 20:20 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 2,118 $2.22 $4,701.96
Disclosure

SEC source: 0000897069-26-001406 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,958

Read SEC document
May 29, 2026 Filed Jun 1, 2026 20:55 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 1,829 $2.57 $4,700.53
Disclosure

SEC source: 0000897069-26-001287 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,840

Read SEC document
May 15, 2026 Filed May 19, 2026 21:37 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 1,583 $2.97 $4,701.51
Disclosure

SEC source: 0000897069-26-001176 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,011

F1 · balance_after: Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 13 shares.

Read SEC document
April 30, 2026 Filed May 1, 2026 20:35 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 1,748 $2.69 $4,702.12
Disclosure

SEC source: 0000897069-26-001002 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,441

Read SEC document
April 15, 2026 Filed Apr 17, 2026 20:51 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 1,583 $2.97 $4,701.51
Disclosure

SEC source: 0000897069-26-000906 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,693

Read SEC document
March 31, 2026 Filed Apr 1, 2026 21:09 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 1,854 $2.54 $4,699.89
Disclosure

SEC source: 0000897069-26-000745 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,110

Read SEC document
January 01, 2026 Filed Feb 4, 2026 22:05 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionRestricted Stock Units · Derivative 193 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-26-000220 · form4.xml · derivative · entry 3

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 193 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Distribution of vested restricted shares.

F1 · derivative.expiration_date: Distribution of vested restricted shares.

Read SEC document
January 01, 2026 Filed Feb 4, 2026 22:05 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 193 $0.00 $0.00
Disclosure

SEC source: 0000897069-26-000220 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,256

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 20:33 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantStock Options (Right to Buy) · Derivative 150,000 $0.00 Strike: $0.20 $0.00
Disclosure

SEC source: 0000897069-25-001553 · form4.xml · derivative · entry 2

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires not disclosed

F2 · derivative.exercise_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

F2 · derivative.expiration_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 20:33 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 50,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-25-001553 · form4.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.

Read SEC document
July 24, 2025 Filed Jul 28, 2025 20:36 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 1,366,046 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-25-001223 · form4.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,376,478

Underlying: Common Stock · 1,366,046 shares

Expires not disclosed

F1 · shares: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,349,245 shares are subject to stockholder approval of the revised Omnibus Plan.

F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.

F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.

Read SEC document
April 01, 2025 Filed Apr 11, 2025 21:20 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 14,482 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-25-000791 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,339

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

Read SEC document
July 10, 2024 Filed Aug 2, 2024 21:12 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 220 $1.71 $376.20
Disclosure

SEC source: 0000897069-24-001608 · form4.xml · nonDerivative · entry 4

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,857

Read SEC document
July 10, 2024 Filed Aug 2, 2024 21:12 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 644 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-24-001608 · form4.xml · nonDerivative · entry 3

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,077

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 21:12 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 339 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001608 · form4.xml · derivative · entry 9

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,914

Underlying: Common Stock · 339 shares

Expires not disclosed

F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 21:12 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 339 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001608 · form4.xml · derivative · entry 8

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,575

Underlying: Common Stock · 339 shares

Expires not disclosed

F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 21:12 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 2,035 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001608 · form4.xml · derivative · entry 7

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,236

Underlying: Common Stock · 2,035 shares

Expires not disclosed

F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.

F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 21:12 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 2,713 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001608 · form4.xml · derivative · entry 6

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,201

Underlying: Common Stock · 2,713 shares

Expires not disclosed

F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.

F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.

Read SEC document
April 05, 2024 Filed Aug 2, 2024 21:12 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 368 $2.79 $1,026.72
Disclosure

SEC source: 0000897069-24-001608 · form4.xml · nonDerivative · entry 2

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,433

Read SEC document
April 05, 2024 Filed Aug 2, 2024 21:12 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 1,675 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-24-001608 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,801

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

Read SEC document
January 01, 2024 Filed Apr 12, 2024 20:50 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionRestricted Stock Units · Derivative 1,675 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-000917 · form4.xml · derivative · entry 4

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,132

Underlying: Common Stock · 1,675 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Distribution of vested restricted shares.

F1 · derivative.expiration_date: Distribution of vested restricted shares.

F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
January 01, 2024 Filed Apr 12, 2024 20:50 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 368 $2.79 $1,026.72
Disclosure

SEC source: 0000897069-24-000917 · form4.xml · nonDerivative · entry 2

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,433

F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
January 01, 2024 Filed Apr 12, 2024 20:50 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 1,675 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-24-000917 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,801

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
October 12, 2023 Filed Oct 12, 2023 22:07 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantCommon Stock 14,771 $0.34 $5,022.14
Disclosure

SEC source: 0000897069-23-001470 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,517

Read SEC document
January 01, 2023 Filed Jan 4, 2023 22:47 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 40,690 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-23-000328 · doc1.xml · derivative · entry 3

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440,328

Underlying: Common Stock · 40,690 shares

Expires not disclosed

F3 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the tssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

F3 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the tssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

Read SEC document
January 01, 2023 Filed Jan 4, 2023 22:47 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 55,107 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-23-000328 · doc1.xml · derivative · entry 2

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 399,638

Underlying: Common Stock · 55,107 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the Issuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

F2 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the Issuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

Read SEC document
December 31, 2022 Filed Jan 4, 2023 22:47 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 10,851 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-23-000328 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344,531

Underlying: Common Stock · 10,851 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units are fully vested on date of grant.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units are fully vested on date of grant.

Read SEC document
September 30, 2022 Filed Oct 3, 2022 20:57 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 10,850 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-018060 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,680

Underlying: Common Stock · 10,850 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
August 05, 2022 Filed Aug 9, 2022 20:23 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 7,601 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-22-015302 · doc1.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,528

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Vesting of time-based restricted shares.

Read SEC document
June 30, 2022 Filed Jul 5, 2022 21:42 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 20,064 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-013686 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,830

Underlying: Common Stock · 20,064 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
April 01, 2022 Filed Apr 11, 2022 21:49 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 247,841 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-008361 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,766

Underlying: Common Stock · 247,841 shares

Expires not disclosed

F1 · derivative.exercise_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan.

F1 · derivative.expiration_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan.

F2 · balance_after: The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person.

Read SEC document
March 31, 2022 Filed Apr 4, 2022 21:53 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 10,715 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-008003 · doc1.xml · derivative · entry 2

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,781

Underlying: Common Stock · 10,715 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 22:30 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,722 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-000300 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,722

Underlying: Common Stock · 6,722 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
December 31, 2021 Filed Jan 6, 2022 22:25 UTC Amendment Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,722 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-000775 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,780

Underlying: Common Stock · 6,722 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance.

Read SEC document
November 01, 2021 Filed Apr 4, 2022 21:53 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 4,286 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-008003 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,066

Underlying: Common Stock · 4,286 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 20:54 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,024 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-017837 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,024

Underlying: Common Stock · 6,024 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
September 30, 2021 Filed Jan 6, 2022 21:00 UTC Amendment Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,024 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-000712 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,058

Underlying: Common Stock · 6,024 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance.

Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:42 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 2,254 $6.20 $13,974.80
Disclosure

SEC source: 0001567619-21-014753 · doc1.xml · nonDerivative · entry 2

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,927

Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:42 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantCommon Stock 7,601 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-21-014753 · doc1.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,181

F1 · price: Vesting of time-based restricted shares.

Read SEC document
August 05, 2021 Filed Aug 9, 2022 20:23 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 1,782 $3.17 $5,648.94
Disclosure

SEC source: 0001567619-22-015302 · doc1.xml · nonDerivative · entry 2

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,746

Read SEC document
July 08, 2021 Filed Jul 9, 2021 20:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 1,907 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-013187 · doc1.xml · derivative · entry 3

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,034

Underlying: Common Stock · 10,034 shares

Expires not disclosed

F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
July 08, 2021 Filed Jul 9, 2021 20:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 12,858 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-013187 · doc1.xml · derivative · entry 2

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,858

Underlying: Common Stock · 12,858 shares

Expires not disclosed

F2 · derivative.exercise_date: The Restricted Stock Units vest upon achievement of certain performance goals.

F2 · derivative.expiration_date: The Restricted Stock Units vest upon achievement of certain performance goals.

Read SEC document
July 08, 2021 Filed Jul 9, 2021 20:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 8,572 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-013187 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,572

Underlying: Common Stock · 8,572 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units vest in two equal installments beginning July 1, 2022.

F1 · derivative.expiration_date: The restricted stock units vest in two equal installments beginning July 1, 2022.

Read SEC document
June 08, 2021 Filed Jun 10, 2021 21:14 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 8,127 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-011989 · doc1.xml · derivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,127

Underlying: Common Stock · 8,127 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.